Post-earnings recap
Reported
Tue, Aug 12, 2025
EPS actual
$-0.66
EPS est.
$-0.85
EPS surprise
+22.81%
1-day move
+2.43%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Mineralys Therapeutics reported a narrower-than-expected EPS loss, which led to a positive stock reaction, rising 2.43%. The company did not disclose revenue figures or future guidance, leaving investors to focus on the EPS surprise as a sign of potential improvement. Overall, the results may indicate progress in their financial performance, but uncertainty remains due to the lack of additional guidance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.66 | N/A | +22.81% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results, highlighting their commitment to pipeline development. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline.